Sanofi-Aventis’ Semuloparin May Have Safety Advantage For ODAC To Consider
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike Pfizer and Eisai’s Fragmin (dalteparin), the new ultra-low-molecular-weight heparin does not appear to carry a hematoma risk.
You may also be interested in...
Lacking A Clear Disease Setting, Sanofi’s Semuloparin Fails ODAC Vote
It isn’t clear to either FDA or the Oncologic Drugs Advisory Committee what specific cancer chemotherapy setting would be the most useful for Sanofi-Aventis’ semuloparin, a low molecular weight heparin intended to prevent venous thromboembolism.
Sanofi-Aventis’ Semuloparin To Face Skeptical FDA At ODAC Meeting
The agency questions the true benefit of the drug in preventing venous thromboembolism in certain cancer patients, even with a more limited population than the sponsor originally asked for.
Onyx’s Kyprolis Heads To ODAC With Open-label Trial; Will Desperation Outweigh Doubts?
Onyx is relying on a single open-label single-arm Phase IIb trial of Kyprolis (carfilzomib) in patients with relapsed and refractory myeloma, which resulted in an overall response rate of 24%